Charles Rowland, Jr. Biography and Net Worth

Director of Viking Therapeutics

Mr. Rowland has more than 30 years of biopharmaceutical industry experience and is currently a board member and strategic advisor for multiple biotechnology companies. He most recently served as the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to his tenure with Aurinia Pharmaceuticals, he was the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was Executive Vice President and CFO, as well as interim co-CEO, for Endo Pharmaceuticals, a specialty pharmaceutical company with $1.3 billion in revenues. He previously held finance and operational positions of increasing responsibility at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines and Nabriva Therapeutics, with previous board appointments including Vitae Pharmaceuticals, BIND Therapeutics, Aurinia Pharmaceuticals and Idenix Pharmaceuticals, among others. Mr. Rowland holds an MBA from Rutgers University and a Bachelor of Science degree from Saint Joseph’s University.

What is Charles A. Rowland, Jr.'s net worth?: The estimated net worth of Charles A. Rowland, Jr. is at least $1.27 million as of May 16th, 2023. Mr. Rowland, Jr. owns 30,000 shares of Viking Therapeutics stock worth more than $1,267,500 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Rowland, Jr. may own. Learn More about Charles A. Rowland, Jr.'s net worth.
How do I contact Charles A. Rowland, Jr.?: The corporate mailing address for Mr. Rowland, Jr. and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on Charles A. Rowland, Jr.'s contact information.
Has Charles A. Rowland, Jr. been buying or selling shares of Viking Therapeutics?: Charles A. Rowland, Jr. has not been actively trading shares of Viking Therapeutics over the course of the past ninety days. Most recently, Charles A. Rowland, Jr. sold 40,000 shares of the business's stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $25.00, for a transaction totalling $1,000,000.00. Following the completion of the sale, the director now directly owns 30,000 shares of the company's stock, valued at $750,000. Learn More on Charles A. Rowland, Jr.'s trading history.
Who are Viking Therapeutics' active insiders?: Viking Therapeutics' insider roster includes Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.
Are insiders buying or selling shares of Viking Therapeutics?: In the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 1,383,618 shares worth more than $81,779,033.02. The most recent insider tranaction occured on November, 8th when Director Lawson Macartney sold 2,000 shares worth more than $137,340.00. Insiders at Viking Therapeutics own 4.7% of the company. Learn More about insider trades at Viking Therapeutics.
Information on this page was last updated on 11/8/2024.

Charles A. Rowland, Jr. Insider Trading History at Viking Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2023	Sell	40,000	$25.00	$1,000,000.00	30,000

Charles A. Rowland, Jr. Buying and Selling Activity at Viking Therapeutics

Viking Therapeutics Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $42.25

$41.97

$45.00

50 Day Range

MA: $58.05

$38.28

$78.03

2 Week Range

Now: $42.25

$17.23

$99.41

Volume

8,815,748 shs

Average Volume

4,483,956 shs

Market Capitalization

$4.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.